Journal of Clinical and Cellular Immunology
Open Access

Guangfu Li

Biography

Dr. Guangfu Li is Assistant Professor, Department of Surgery, Medical University of South Carolina, USA. He had developed and produced some engineered products including recombinant interferon-a (IFN-a), recombinant human parathyroid hormone (PTH), bispecific engineering antibody of anti-RBC and anti-HFRSV, and new type of recombinant vaccine adjuvant CpG. Using cell or animal systems. Dr. Guangfu Li worked with Dr. Kevin F. Staveley-O’Carroll for dissecting tumor-induced immunotolerance in hepatocellular cancer and developing innovative therapeutic strategies. Using the established orthotopic murine model, they found that sunitinib, a FDA-approved chemotherapy agent, prevents tumor-induced immunotolerance through modulating tumor-induced tolerant environment, and the combination of sunitinib with adoptive transfer of tumor antigen-specific T-cells completely eradicates the established tumors. Dr. Guangfu Li research interests include Translational cancer research, Cancer Immunotherapy, Cancer chemo-immunotherapy, DC-based cancer immunotherapy, iPSC-based cancer immunotherapy, STAT3 signaling and function, Macrophage and cancer.

Research Interest

Translational cancer research, Cancer Immunotherapy, Cancer chemo-immunotherapy, DC-based cancer immunotherapy, iPSC-based cancer immunotherapy, STAT3 signaling and function, Macrophage and cancer.